Ken Griffin Anebulo Pharmaceuticals, Inc. Call Options Transaction History
Citadel Advisors LLC
- $509 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ANEB
# of Institutions
19Shares Held
22.6MCall Options Held
0Put Options Held
0-
22 Nw, LP Seattle, WA15.5MShares$16.9 Million18.74% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.04MShares$3.31 Million0.18% of portfolio
-
Mangrove Partners New York, NY2.53MShares$2.75 Million0.52% of portfolio
-
Morgan Stanley New York, NY399KShares$435,1480.0% of portfolio
-
Lvw Advisors, LLC350KShares$381,0820.06% of portfolio
About Anebulo Pharmaceuticals, Inc.
- Ticker ANEB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,633,200
- Market Cap $27.9M
- Description
- Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The ...